Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension

J. Y. Findlay, B. A. Harrison, D. J. Plevak, M. J. Krowka

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Pulmonary artery hypertension in association with liver failure (portopulmonary hypertension [PPHTN]) is a significant barrier to liver transplantation because patients with this condition have a very high mortality when transplantation is undertaken. Inhaled nitric oxide (NO), a potent pulmonary vasodilator, reduces pulmonary artery pressure (PAP) in some patients with primary pulmonary hypertension, but its effect in patients with PPHTN is controversial. We investigated the hemodynamic effects of inhaled NO in 6 patients with PPHTN. Five of 6 patients responded to NO inhalation with decreases in PAP and pulmonary vascular resistance of greater than 10%; these decreases were statistically significant at NO concentrations of 10 and 30 ppm. Cardiac output did not significantly change. We conclude that inhalation of NO reduces PAPs in some patients with PPHTN.

Original languageEnglish (US)
Pages (from-to)381-387
Number of pages7
JournalLiver Transplantation and Surgery
Issue number5
StatePublished - 1999

ASJC Scopus subject areas

  • Surgery
  • Hepatology


Dive into the research topics of 'Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension'. Together they form a unique fingerprint.

Cite this